Daniel A. Laheru

2001–2025 年に発表

105
論文数
33,957
被引用数
78
h 指数
101
i10 指数

被引用数

Daniel A. Laheru の年別被引用数1986 年: 被引用 1 件1996 年: 被引用 1 件2001 年: 被引用 4 件2002 年: 被引用 13 件2003 年: 被引用 14 件2004 年: 被引用 18 件2005 年: 被引用 25 件2006 年: 被引用 40 件2007 年: 被引用 32 件2008 年: 被引用 41 件2009 年: 被引用 62 件2010 年: 被引用 70 件2011 年: 被引用 109 件2012 年: 被引用 119 件2013 年: 被引用 164 件2014 年: 被引用 271 件2015 年: 被引用 454 件2016 年: 被引用 468 件2017 年: 被引用 520 件2018 年: 被引用 502 件2019 年: 被引用 1,551 件2020 年: 被引用 1,805 件2021 年: 被引用 1,772 件2022 年: 被引用 1,303 件2023 年: 被引用 978 件2024 年: 被引用 1,448 件2025 年: 被引用 713 件2026 年: 被引用 19 件1987〜1995 年は被引用が無いため表示していません1997〜2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,397 件、この内訳の 28.4%中国: 引用元論文 2,123 件、この内訳の 13.7%ドイツ: 引用元論文 832 件、この内訳の 5.4%イタリア: 引用元論文 825 件、この内訳の 5.3%イギリス: 引用元論文 770 件、この内訳の 5%日本: 引用元論文 663 件、この内訳の 4.3%フランス: 引用元論文 560 件、この内訳の 3.6%スペイン: 引用元論文 460 件、この内訳の 3%オーストラリア: 引用元論文 426 件、この内訳の 2.7%オランダ: 引用元論文 424 件、この内訳の 2.7%カナダ: 引用元論文 388 件、この内訳の 2.5%韓国: 引用元論文 359 件、この内訳の 2.3%
0%28.4%その他 21.1%

分野

  • Medicine59.2%
  • Biochemistry, Genetics and Molecular Biology29.9%
  • Immunology and Microbiology6.9%
  • Engineering1.1%
  • Materials Science1.1%
  • Neuroscience0.4%
  • その他1.4%

トピック

  • Pancreatic and Hepatic Oncology Research12%
  • Cancer Genomics and Diagnostics8.8%
  • Cancer Immunotherapy and Biomarkers6.4%
  • Cancer Cells and Metastasis3.9%
  • Immunotherapy and Immune Responses3.6%
  • Cholangiocarcinoma and Gallbladder Cancer Studies2.1%
  • その他63.2%

共著者

全論文

検索で開く
  1. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore‐Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba‐Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian‐Li Wang, Jon Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Díaz - Science Translational Medicine 2014 被引用: 5,110

  2. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 被引用: 6,661

  3. Targeting neoantigens to augment antitumour immunity

    著者: , , , , - Nature reviews. Cancer 2017 被引用: 1,032

  4. Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mark Yarchoan - Nature Cancer 2021 被引用: 346

  5. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

    著者: , , , , , , , , , , - JCI Insight 2019 被引用: 538

  6. Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 600

  7. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

    著者: , , , , , , , , , , , , , , , , - Cancer Immunology Research 2014 被引用: 544

  8. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lei Zheng - Cancer Cell 2022 被引用: 178

  9. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 180

  10. Metastatic Pancreatic Cancer: ASCO Guideline Update

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 289

  11. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 被引用: 83

  12. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 152

  13. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

    著者: , , , , , , , , , , - Journal of Immunotherapy 2013 被引用: 554

  14. A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 127

  15. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer

    著者: , , , , , , , , , , , , , - JAMA Oncology 2019 被引用: 290

  16. Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hao Wang, Joel Sunshine, Robert J. Johnston, Julie S. Deutsch, Janis M. Taube, Robert A. Anders, Elizabeth M. Jaffee, Elana J. Fertig, Mark Yarchoan - Nature Immunology 2024 被引用: 89

  17. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

    著者: , , , , , , , , , , , , , , , , - British Journal of Cancer 2019 被引用: 170

  18. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

    著者: , , , , , , , , , , , , , - Annals of Surgery 2018 被引用: 394

  19. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

    著者: , , , , , , , , , , , , , , , , , - Journal of Immunotherapy 2014 被引用: 394

  20. A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

    著者: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2011 被引用: 368

  21. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jin He, Christopher L. Wolfgang, Elizabeth D. Thompson, Robert A. Anders, Elizabeth A. Sugar, Elizabeth M. Jaffee, Daniel A. Laheru - Clinical Cancer Research 2020 被引用: 77

  22. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 193

  23. Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 被引用: 1,045

  24. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 1,078